Mirvaso FDA Approval History
Mirvaso (brimonidine) topical gel is an alpha adrenergic agonist indicated for the topical treatment of facial erythema of rosacea.
Development timeline for Mirvaso
|Aug 26, 2013||Approval Galderma Receives FDA Approval of Mirvaso for the Topical Treatment of Facial Erythema of Rosacea|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.